Active ingredientPrazosin HClCat. No. P-P175-001CAS 19237-84-4Family · Pharmaceutical analytical standards
Prazosin
An alpha-1 blocker patented in 1965 and in medical use since 1974 for high blood pressure; it is also used for urinary symptoms caused by an enlarged prostate. This family brings together the active ingredient, pharmacopoeial impurities, metabolites and labelled standards.
Did you know?In the 1990s Murray Raskind and colleagues, studying it in veterans with urinary problems, noticed that it reduced the nightmares of post-traumatic stress disorder.
Go to the active ingredient →Active ingredientPrazosin HClCat. No. P-P175-001CAS 19237-84-4
MetabolitePrazosin N-GlucuronideCat. No. P-P175-003CAS 944943-73-1
Isotopically labelledPrazosin-d8Cat. No. P-P175-004CAS 1006717-55-0
Pharmacopoeial impurityPrazosin EP Impurity DCat. No. P-P175-006CAS 40172-95-0No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Reference substancePrazosin hydrochloride CRSEDQM code P2680000Family Prazosin
ImpurityPrazosin impurity A CRSEDQM code Y0002095Family PrazosinNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.